Therapeutic Rivaroxaban Dose: Risk Outweighs Benefit in Stable COVID

In stable patients hospitalized with COVID-19 and elevated D-dimer levels, therapeutic anticoagulation with rivaroxaban 20 mg once daily did not improve clinical outcomes but did increase bleeding compared with in-hospital prophylactic anticoagulation in the ACTION trial. The trial also intended to test a therapeutic regimen of enoxaparin (1 mg/kg twice daily) in unstable patients but did […]

Read More